CDNA - CareDx, Inc
After hours:
| Previous Close | 8.09 |
| Open | 8.10 |
| Bid | 7.60 x 800 |
| Ask | 7.97 x 900 |
| Day's Range | 7.91 - 8.22 |
| 52 Week Range | 6.22 - 27.35 |
| Volume | |
| Avg. Volume | 1,365,746 |
| Market Cap | 428.193M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.80 |
Business WireCareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum
BRISBANE, Calif., May 16, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase its digital health portfolio and host a symposium which addresses barriers in access to transplantation at the 31st Annual UNOS Transplant Management Forum (TMF) taking place May 16-18 in Denver, Colo
Simply Wall St.What Does The Future Hold For CareDx, Inc (NASDAQ:CDNA)? These Analysts Have Been Cutting Their Estimates
The analysts covering CareDx, Inc ( NASDAQ:CDNA ) delivered a dose of negativity to shareholders today, by making a...
ZacksCareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates
CareDx (CDNA) delivered earnings and revenue surprises of -57.14% and 3.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireCareDx Reports First Quarter 2023 Results
BRISBANE, Calif., May 10, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the first quarter ended March 31, 2023.
Business WireCareDx to Report First Quarter 2023 Financial Results
BRISBANE, Calif., May 08, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Business WireCareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference
BRISBANE, Calif., April 25, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it will showcase the latest developments across its AlloSeq®* portfolio during the 36th European Immunogenetics and Histocompatibility Conference taking place April 26-29 in Nantes, France.
Business WireCareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation
BRISBANE, Calif., April 19, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 43rd annual meeting & scientific sessions of the International Society for Heart and Lung Transplantation (ISHLT) with over 55 oral presentations and posters, and two symposia covering the lates
- Simply Wall St.
CareDx, Inc's (NASDAQ:CDNA) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 1.6x CareDx, Inc ( NASDAQ:CDNA ) may be sending very bullish signals at the...
Business WireNational Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community
BRISBANE, Calif., April 06, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the National Kidney Foundation honored CareDx with a corporate citizenship award during its 41st Annual Kidney Ball held on March 31, 2023, in Washington, D.C.
Business WireCareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation
BRISBANE, Calif. & EDEN PRAIRIE, Minn., April 05, 2023--CareDx, Inc. (Nasdaq: CDNA) and Miromatrix Medical Inc. ("Miromatrix") (Nasdaq: MIRO) – today announced an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs.
Business WireCareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association
BRISBANE, Calif., March 23, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced its gold-level sponsorship and participation at the 12th Congress of the International Pediatric Transplant Association (IPTA) taking place March 25-28, 2023, in Austin, Texas.
Business WireThe American Society of Transplant Surgeons Position Statement Supports Use of CareDx’s AlloSure Kidney for Organ Transplant Surveillance
BRISBANE, Calif., March 07, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the issuance of a new position statement by the American Society of Transplant Surgeons (ASTS) supporting the use of CareDx’s AlloSure® Kidney for organ transplant surveillance, and AlloSure Heart and AlloMap® Heart.
Business WireCareDx Update Regarding Raymond James & Associates’ Conference
BRISBANE, Calif., March 06, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company has determined not to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference scheduled for later today in light of scheduling conflicts. The company looks forward to providing
Business WireCareDx To Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
BRISBANE, Calif., March 06, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference.
Business WireCareDx Comments on MolDX Publication of New Billing and Coding Article
BRISBANE, Calif., March 03, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today commented on the release of a Billing Article related to MolDX Molecular Testing for Solid Organ Allograft Rejection that covers AlloSure® and AlloMap®. The Billing Article is effective March 31, 2023.
Business WireCareDx Key Supporter of the National Kidney Foundation’s Annual Kidney Patient Summit
BRISBANE, Calif., March 01, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is sponsoring the National Kidney Foundation (NKF) Annual Kidney Patient Summit taking place on Capitol Hill on March 1-2, 2023.
- Simply Wall St.
CareDx Full Year 2022 Earnings: In Line With Expectations
CareDx ( NASDAQ:CDNA ) Full Year 2022 Results Key Financial Results Revenue: US$321.8m (up 8.6% from FY 2021). Net...
- Zacks
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireCareDx Reports Fourth Quarter and Full Year 2022 Results
BRISBANE, Calif., February 27, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported financial results for the fourth quarter and full year ended December 31, 2022.
Business WireCareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting
BRISBANE, Calif., February 22, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced that it is showcasing the clinical value of multimodality and artificial intelligence innovation at the annual American Society of Transplantation Cutting Edge of Transplantation (CEoT) meeting taking place February
Business WireCareDx to Report Fourth Quarter and Full Year 2022 Financial Results
BRISBANE, Calif., February 21, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p
ZacksAnalysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksEarnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.